Auxetics

Auxetics is a biomechanics-driven medical device startup targeting the significant unmet need in venous disease treatment, specifically post-thrombotic syndrome (PTS). The company's lead product is a novel auxetic venous stent designed to mitigate stent-adjacent stenosis (SAS), a common complication of current stents that reduces venous inflow and worsens outcomes. By applying both radial and longitudinal force, the stent aims to preserve the natural geometry of the vein, potentially improving long-term patency and patient quality of life. The company is in the pre-clinical/development stage, led by a team of physicians and engineers, and is positioned to address a large and growing global market for venous interventions.

Auxetic stent geometry (negative Poisson's ratio) that expands both radially and longitudinally to mitigate stent-adjacent stenosis (SAS) in venous applications.

The venous stent market is competitive, featuring products from major players like Boston Scientific (Vici, Venovo), Medtronic (Abre), and BD (Bentley). These companies have significant sales forces and clinical data. Auxetics' competition is differentiated by its novel biomechanical approach aimed at solving a specific complication (SAS), rather than just improving radial strength or flexibility. Its success hinges on proving this differentiation translates to superior clinical outcomes.